Qube Research & Technologies (QRT)’s Viridian Therapeutics VRDN Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-231,270	Closed	-$4.52M	–	4137
2026 Q1	$4.52M	Buy	231,270 +101,738	+79%	+$3.02M	0.01%	1715
2025 Q4	$4.03M	Buy	+129,532	New	+$3.55M	﹤0.01%	1890
2025 Q1	–	Sell	-28,809	Closed	-$552K	–	3914
2024 Q4	$552K	Buy	+28,809	New	+$626K	﹤0.01%	2425
2022 Q2	–	Sell	-33,187	Closed	-$614K	–	3179
2022 Q1	$614K	Buy	33,187 +16,187	+95%	+$311K	0.01%	1431
2021 Q4	$336K	Buy	+17,000	New	+$317K	﹤0.01%	1753
2020 Q4	–	Sell	-24,447	Closed	-$284K	–	2242
2020 Q3	$284K	Buy	24,447 +20,447	+511%	+$305K	﹤0.01%	1267
2020 Q2	$67K	Buy	+4,000	New	+$45.4K	﹤0.01%	1566

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Qube Research & Technologies (QRT)'s VRDN Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 231,270 shares — an estimated $4.52M sold.

Qube Research & Technologies (QRT) first reported a position in VRDN in Q2 2020 and held it in 7 quarters. The position peaked at $4.52M in Q1 2026. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Qube Research & Technologies (QRT) reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 231,270 Viridian Therapeutics shares in Q2 2026, an estimated $4.52M.
Qube Research & Technologies (QRT) first reported a position in Viridian Therapeutics in Q2 2020 and held it in 7 quarters.
Qube Research & Technologies (QRT)'s Viridian Therapeutics position peaked at $4.52M in Q1 2026.
215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.